Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK3965193
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GSK3965193 is an investigational small molecule drug developed by GSK for the treatment of chronic hepatitis B infection. It acts as a dual inhibitor of Poly(A) polymerase non-canonical PAPD5 (PAPD5) and Terminal nucleotidyltransferase 4A (PAPD7), enzymes involved in the stability and processing of viral RNA. By inhibiting these targets, GSK3965193 aims to reduce levels of hepatitis B surface antigen (HBsAg), a key marker for active infection, potentially contributing to functional cure strategies for chronic hepatitis B. The drug is currently being evaluated in Phase 2 clinical trials both as monotherapy and in combination with bepirovirsen.
02
Targets
TENT4BTENT4A (Terminal nucleotidyltransferase 4A)
Beyond the preview
Go deeper on GSK3965193.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK3965193.